Vyvgart
VYVGART is an FDA-approved treatment for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG).
VYVGART is an FDA-approved treatment for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG).
VYVGART is given in treatment cycles of a 1-hour infusion each week for 4 weeks (4 infusions total).
During each infusion a healthcare professional will:
Your neurologist and insurance company will work together to determine where you will receive your infusions. It will most likely be at your neurologist’s office or an infusion center.
VYVGART was safe in treating most clinical trial participants. In the clinical trial, the following side effects were reported in at least 5% of participants on VYVGART and more frequently than in participants on placebo.
Most infections in participants on VYVGART were mild to moderate. Additionally, more patients on VYVGART vs placebo had blood side effects that were mild to moderate.